When it comes to Active Surveillance (AS) decisions, there’s good news and bad news. The good news: based on biopsy results, more doctors are recommending AS for prostate cancer (PCa) patients with insignificant disease. The bad news: the biopsy might have missed significant PCa so the patient can’t know for sure if AS is a keep reading